{"schema_version":"secwatch.filing_event.v1","accession":"0001062993-25-012044","form_type":"8-K","ticker":"MDCX","cik":"0001997296","company_name":"Medicus Pharma Ltd.","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.658485+00:00","generated_at":"2026-05-19T00:16:44.248275+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Medicus Pharma appoints Andrew Smith COO; Phase 2 BCC trial randomized >50 of 90 patients","bullets":["Andrew Smith appointed COO effective June 30, 2025; base salary $325K, 100k stock options at $2.60 vesting quarterly over 5 years.","Phase 2 SKNJCT-003 for BCC using D-MNA has randomized >50 of 90 patients across 9 US sites; interim analysis showed >60% clinical clearance (preliminary).","Clinical expansion: European sites plus UAE study SKNJCT-004 (36 patients, 4 sites); Cleveland Clinic Abu Dhabi as PI.","Previously announced binding LOI to acquire Antev Ltd. for Teverelix GnRH antagonist; no new terms disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-25-012044","json":"https://secwatch.observer/filing/0001062993-25-012044.json","markdown":"https://secwatch.observer/filing/0001062993-25-012044.md","text":"https://secwatch.observer/filing/0001062993-25-012044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1997296/000106299325012044/0001062993-25-012044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1997296/000106299325012044/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T00:16:44.248275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6572bc495e","claim":"Andrew Smith was appointed as Chief Operating Officer at Medicus Pharma Ltd..","evidence_excerpt":"On June 23, 2025, Medicus Pharma Ltd. (the \"Company\") announced the appointment of Andrew Smith, age 57, to serve as the Company's Chief Operating Officer (\"COO\").","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1997296/000106299325012044/0001062993-25-012044-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}